Should You Continue to Hold LH Stock in Your Portfolio?

Labcorp expands in specialty testing and ramps up acquisitions, but macro pressures and currency headwinds complicate its growth outlook.

Zacks Investment Research • Dec 2, 2025

Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp

FRANKLIN, Tenn. & BURLINGTON, N.C.--(BUSINESS WIRE)--Community Health Systems, Inc. (the “Company”) (NYSE: CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has completed the sale of select assets of the ambulatory outreach laboratory services of CHS-affiliated health systems in 13 states, including certain patient service centers and in-office phlebotomy locations, to Labcorp (NYSE: LH) for approximately $194 million cash, before certain transaction expenses.

Business Wire • Dec 2, 2025

Labcorp (LH) Up 8.1% Since Last Earnings Report: Can It Continue?

Labcorp (LH) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Nov 27, 2025

Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Nov 25, 2025

Labcorp Appoints Victor Bulto to Board of Directors

Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.

PRNewsWire • Nov 24, 2025

LH Shares Gain Following Publication of New Plasma Detect MRD Data

Labcorp shares edge higher as new studies spotlight Plasma Detect's role in tracking MRD and improving post-surgery cancer detection.

Zacks Investment Research • Nov 21, 2025

Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research

Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research BURLINGTON, N.C. , Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two recent peer-reviewed publications – Nature Medicine and Clinical Cancer Research.

PRNewsWire • Nov 19, 2025

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

DURHAM, N.C. and SEOUL, South Korea , Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

PRNewsWire • Nov 17, 2025

Labcorp lifts annual profit forecast on strong diagnostic test demand

Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator benefited from strong demand for its diagnostic tests.

Reuters • Oct 28, 2025

Labcorp Positioned For Gradual Upside With Resilient Margins And Dividend Support

Laboratory Corp (NYSE: LH) reported third-quarter 2025 adjusted earnings per share of $4.18 on Tuesday, up from $3.50 a year ago, beating the consensus of $4.18.

Benzinga • Oct 28, 2025